Patents by Inventor Paul R. Ervin
Paul R. Ervin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110130302Abstract: The present invention provides methods for preparing drug response and/or resistance profiles for breast tumor specimens, or cells derived therefrom. The drug response and/or resistance profiles are useful for determining effective chemotherapeutic agents for treatment of the tumor or cell to thereby individualize patient therapy. In other aspects, the invention provides a method for identifying a pathway or gene expression signature indicative of a breast cancer cell's sensitivity to a chemotherapeutic agent, which is useful for identifying a population response rate, or patient sub-population likely to respond to the drug candidate.Type: ApplicationFiled: December 1, 2010Publication date: June 2, 2011Applicant: Precision Therapeutics, Inc.Inventors: Kui SHEN, Nan Song, Shara D. Rice, Dakun Wang, David A. Gingrich, Zhenyu Ding, Chunqiao Tian, Stacey L. Brower, Paul R. Ervin, Michael Gabrin
-
Publication number: 20110129822Abstract: The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and/or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and/or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.Type: ApplicationFiled: December 1, 2010Publication date: June 2, 2011Applicant: Precision Therapeutics, Inc.Inventors: Kui SHEN, Nan Song, Shara D. Rice, Dakun Wang, David A. Gingrich, Zhenyu Ding, Chunqiao Tian, Stacey L. Brower, Paul R. Ervin, Michael Gabrin
-
Publication number: 20110039279Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: ApplicationFiled: September 22, 2010Publication date: February 17, 2011Inventor: Paul R. Ervin, JR.
-
Publication number: 20110014644Abstract: The present invention provides methods for individualizing therapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more antifolate therapeutic agents prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an antifolate agent, such as pemetrexed or methotrexate.Type: ApplicationFiled: June 22, 2010Publication date: January 20, 2011Applicant: Precision Therapeutics, Inc.Inventors: Sarah L. Suchy, Stacey L. Brower, Paul R. Ervin
-
Publication number: 20110003318Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.Type: ApplicationFiled: July 29, 2010Publication date: January 6, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Paul R. Ervin, JR.
-
Publication number: 20090011434Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: ApplicationFiled: February 7, 2008Publication date: January 8, 2009Applicant: The Regents of the University of MichiganInventor: Paul R. Ervin, JR.
-
Patent number: 7332287Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: GrantFiled: July 9, 2002Date of Patent: February 19, 2008Assignee: The Regents of the University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 7323173Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: GrantFiled: July 9, 2002Date of Patent: January 29, 2008Assignee: The Regents of the University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 7256277Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.Type: GrantFiled: June 11, 2003Date of Patent: August 14, 2007Assignee: Regents of the University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 6939714Abstract: Epithelial cell growth inhibitors differentially express in normal and cancerous epithelial cells. The ECGI proteins and nucleic acid sequence encoding them are useful in the diagnosis and treatment of epithelial cell cancers, for example prostate, ovarian, colon cancer, and the like.Type: GrantFiled: December 18, 2001Date of Patent: September 6, 2005Assignee: Biotherapies, Inc.Inventor: Paul R. Ervin, Jr.
-
Publication number: 20030212263Abstract: An Allelic varian of Mammastatin, MammC, nucleic acid sequence encoding the variant Mammastatin, and methods for breast cancer diagnosis and therapy using the variant sequence of the invention.Type: ApplicationFiled: December 19, 2002Publication date: November 13, 2003Applicants: The University of Michigan, Paul R. Ervin, Jr.Inventor: Paul R. Ervin
-
Publication number: 20030157576Abstract: Epithelial cell growth inhibitors differentially express in normal and cancerous epithelial cells. The ECGI proteins and nucleic acid sequence encoding them are useful in the diagnosis and treatment of epithelial cell cancers, for example prostate, ovarian, colon cancer, and the like.Type: ApplicationFiled: December 18, 2001Publication date: August 21, 2003Inventor: Paul R. Ervin
-
Patent number: 6599495Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.Type: GrantFiled: August 22, 2000Date of Patent: July 29, 2003Assignee: Regents of the University of MichiganInventor: Paul R. Ervin, Jr.
-
Publication number: 20030108961Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: ApplicationFiled: July 9, 2002Publication date: June 12, 2003Applicant: The University of MichiganInventor: Paul R. Ervin
-
Publication number: 20030095972Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: ApplicationFiled: July 9, 2002Publication date: May 22, 2003Applicant: The University of MichiganInventor: Paul R. Ervin
-
Patent number: 6500937Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.Type: GrantFiled: December 19, 1997Date of Patent: December 31, 2002Assignee: University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 6492504Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: GrantFiled: August 6, 1999Date of Patent: December 10, 2002Assignee: The University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 6451765Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: GrantFiled: April 2, 1999Date of Patent: September 17, 2002Assignee: University of MichiganInventor: Paul R. Ervin, Jr.
-
Publication number: 20020072592Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the ?administration of phosphorylated Mammastatin.Type: ApplicationFiled: August 6, 1999Publication date: June 13, 2002Inventor: PAUL R. ERVIN, JR.
-
Patent number: 5255809Abstract: A container (10) for compressed gas with a pressure relief member (18) made from a bimorph shape memory material. The bimorph (18) is impermeable by the gas. The bimorph (18) assumes a shape which changes depending on temperature. Below a critical temperature, the bimorph (18) lies in a first (deformed) state, and reverts to a second (remembered) state thereabove. The gas is entrapped within the container (10) when the bimorph (18) assumes the first state. When pressure rises due to temperature increase above the critical temperature, gas may escape from the container (10). This is because the bimorph (18) reverts to its second state, in which a relief gas passageway is opened, thereby relieving gas pressure.Type: GrantFiled: May 17, 1993Date of Patent: October 26, 1993Assignee: Ford Motor CompanyInventors: Paul R. Ervin, Ronald C. Malec, Alan J. Porter